Anti-IL-5 therapies for chronic obstructive pulmonary disease

Area of Science:

• Pulmonology
• Immunology
• Pharmacology

Background:

• Exacerbations of chronic obstructive pulmonary disease (COPD) significantly contribute to hospital admissions, morbidity, and mortality.
• COPD exhibits diverse inflammatory phenotypes, including eosinophilia, which can precipitate acute exacerbations in specific patient subgroups.
• Interleukin-5 (IL-5) targeting monoclonal antibodies, effective in severe eosinophilic asthma, may offer therapeutic benefits for COPD patients with an eosinophilic phenotype.

Purpose of the Study:

• To evaluate the efficacy and safety of monoclonal antibody therapies targeting IL-5 signaling (anti-IL-5 or anti-IL-5Rα) versus placebo in adults with COPD.

Main Methods:

• Systematic review and meta-analysis of randomized controlled trials comparing anti-IL-5 therapies with placebo in adult COPD patients.
• Searched multiple databases including Cochrane Airways Trials Register, CENTRAL, MEDLINE, and Embase up to September 23, 2020.
• Primary outcomes included exacerbations requiring antibiotics or oral steroids, COPD hospitalizations, serious adverse events, and quality of life, analyzed using random-effects models with GRADE certainty assessment.

Main Results:

• Mepolizumab (100 mg) reduced moderate/severe exacerbations by 19% in COPD patients with ≥150/μL eosinophils (high-certainty evidence) and increased time to first exacerbation (high-certainty evidence).
• Benralizumab (100 mg) reduced severe, hospitalization-requiring exacerbations by 37% in patients with ≥220/μL eosinophils (high-certainty evidence).
• Both therapies demonstrated a favorable safety profile with no significant difference in serious adverse events compared to placebo; quality of life improvements were minimal.

Conclusions:

• Mepolizumab and benralizumab likely reduce exacerbation rates in selected COPD patients with elevated blood eosinophils, supporting personalized treatment strategies.
• The findings underscore the importance of disease phenotyping in COPD management.
• Further research is warranted to define optimal blood eosinophil thresholds for treatment efficacy and to assess cost-effectiveness.